3647 results for «686»
3647 results
M-TEER for primary mitral regurgitation
08 Feb 2025 – From PCR Tokyo Valves 2025
In this PCR Tokyo Valves 2025 session on M-TEER for primary mitral regurgitation, gain valuable insights starting with an overview of current TEER devices. Benefit from four case studies that highlight the features of these devices, explore strategies to prevent mitral regurgitation recurrence post-TEER, and delve...
M-TEER around the world
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore the latest insights and advancements in the field of Mitral Transcatheter Edge-to-Edge Repair (M-TEER) from around the world. Discover a new anatomical risk score for predicting procedural outcomes, two-year outcomes from the MiCLASP study, the impact of regurgitant volume to left atrial volume ratio on...
M-TEER difficult situation: small mitral valves, P2 prolapse & leaflet degeneration
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore a series of challenging cases in Mitral Transcatheter Edge-to-Edge Repair (M-TEER), highlighting the versatility and adaptability of this technique. Discover how M-TEER can be successfully applied in patients with extremely small mitral valves, P2 prolapse supported by chordae from the posterior papillary muscle, wide prolapse...
TAVI complications: hemolytic anemia, prosthetic valve endocarditis & stroke
08 Feb 2025 – From PCR Tokyo Valves 2025
Gain valuable insights into the management of complications associated with Transcatheter Aortic Valve Implantation (TAVI). Discover the latest evidence on hemolytic anemia, the predictive value of the hemoglobin to creatinine ratio, outcomes of transcarotid TAVI, a case study on prosthetic valve endocarditis, the role of diastolic...
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Author